Postprandial hypoglycemia is one of the main complications of bariatric surgery and can affect up to 30% of patients. Unlike ...

With data 'locked' in medical devices, sociologist Shane O'Donnell explains how people with Type 1 diabetes are turning to ...

The FDA has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism.

A study conducted by a Brazilian researcher at Harvard shows that serotonin – a hormone known for regulating mood – plays a ...

In a report released on December 3, Julian Harrison from BTIG maintained a Buy rating on Rezolute (RZLT – Research Report), with a price target ...

Amylyx (AMLX) announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist, for the ...

If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class ...

Rezolute is advancing treatments for Congenital Hyperinsulinism and Diabetic Macular Edema with RZ402. Learn why RZLT stock ...

Rezolute, Inc. (RZLT),a late-stage biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has ...

Rezolute received an orphan-drug designation from the Food and Drug Administration for its treatment of hypoglycemia, or low blood sugar, caused by a disease in which a tumor produces too much insulin ...